(NYSE: PFE) may not be the must-have pharmaceutical investment it was at one point. If your priority is reliable divided income, however, the drugmaker remains a rock-solid pick. Not only has it paid a dividend like clockwork for decades, the company has regularly raised its annual payout in recent years. Now that the dividend is well established, this streak isn't apt to end in the foreseeable future.

You know the company perhaps better than you realize. Blockbuster drugs like cancer-fighting Ibrance, pneumonia vaccine Prevnar, and blood-thinner Eliquis are all part of Pfizer's portfolio.

None of them hold a candle to Pfizer's (and the world's) best-selling drug of all time, of course. That's anti-cholesterol treatment Lipitor, which finally lost its patent protection in late 2011. The company has not been quite the same since, unable to replace Lipitor's revenue with any single drug. The stock has lagged accordingly.

Continue reading

Source Fool.com